This site is intended for health professionals only!

Published on 7 July 2010

Share this story:
Twitter
LinkedIn

Breast cancer drug draws closer

teaser

An innovative breast cancer treatment has taken a step closer to the market as Swiss drugmaker Roche Holding AG submitted it for approval with American health regulators.

Roche revealed it filed trastuzumab-DM1 (T-DM1) – aimed at people with advanced HER2-positive breast cancer who had previously received other treatments – to the US Food and Drug Administration (FDA).

The company claims that its study has demonstrated that the drug shrank tumours in a third of women who had received an average of seven prior medicines for advanced HER2-positive breast cancer.

Roche also predicts that the new drug could eventually bring in sales of over £1.24 billion ($1.88 billion).

The news will also come as a boost for ImmunoGen, as the drug includes ImmunoGen’s DM1 cancer-cell killing agent linked to the HER2-targeting antibody trastuzumab, or Herceptin. This would be the first product developed by ImmunoGen filed for approval.

When HER2-positive breast cancer is advanced, it means the disease has spread to other parts of the body, normally the brain, lungs, bones, and liver.

Copyright Press Association 2010

FDA



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn